Asia-pacific Male Infertility Market 2023-2030

Asia-pacific Male Infertility Market 2023-2030

MARKET OUTLOOK

Triton’s research report on the Asia-Pacific male infertility market states that the market is projected to progress with a CAGR of 5.38% during the forecast period 2023-2030. India, South Korea, China, Japan, Australia & New Zealand, ASEAN countries, and Rest of Asia-Pacific are studied in the region’s report.

In India, the male infertility market is experiencing significant growth due to increasing awareness about infertility, leading to a higher demand for effective treatments. Male infertility accounts for almost 50% of infertility cases in India, with a prevalence rate of 23%, according to the World Health Organization. This decline in sperm count increased the need for treatments, which may generate opportunities for the male infertility market in the country.

During the forecast period, the male infertility market in South Korea is expected to grow due to significant lifestyle changes, a higher incidence of diseases like diabetes, and increased utilization of assisted reproductive technologies (ARTs). According to the National Center for Biotechnology Information, in 2020, diabetes mellitus affected around 16.7% of the population. Hence, all these factors widen the scope and growth of the studied market.

COMPETITIVE OUTLOOK

The leading companies in the male infertility market comprise Vitrolife, Bayer AG, Aytu BioPharma, Zydus Lifesciences Limited, and CinnaGen Co.